EN DE
Watch Ginwa Enterprise Group Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Ginwa Enterprise Group Inc (600080) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Ginwa Enterprise Group Inc stock ¥0.76, price ¥3.93, that is 80.7% below the price, quality 42 out of 100. Rating: strongly overvalued. Calculated from audited financials with 15 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN · ISIN CNE000000QQ8

GE Ginwa Enterprise Group Inc logo Thin data Nov 6, 2026

Ginwa Enterprise Group Inc

600080 · SHG
Very expensive, weak quality

Our calculation puts a fair price 81% below what the stock costs today.

Low debt
Quality 42/100
Thin margins · 1.9% net margin (TTM)
0.8% dividend yield · Token dividend
Costs 131 times its yearly profit.
Fair value ¥0.7600 · Strongly overvalued
Weak Growth (revenue 5y −4.0 %/yr in CNY)
Negative free cash flow
Trails peers (2/13)
Narrow moat 24/100
Thin data
Watch Ginwa Enterprise Group Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥10.87 ¥3.90 Fair Value ¥0.7600 May 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range ¥3.90 – ¥10.87 · fair‑value band ¥0.5300 – ¥0.9900 · the ¥3.93 price screens above the ¥0.7600 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 6, 2026.

Follow Ginwa Enterprise Group in your weekly email

Every Wednesday you see whether Ginwa Enterprise Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Ginwa Enterprise (Group) Inc. researches, develops, produces, markets, and sells traditional Chinese medicines, biological drugs, and chemical drugs primarily in China.

Show moreShow less

The company offers a range of orthopaedics, immunity, children, and general medicines in various dosage forms, including tablets, capsules, granules, powders, mixtures, oral solutions, syrups, and external solutions. It is also involved in the pharmaceutical logistics activities.

The company was founded in 1996 and is headquartered in Xi'an, China.

Stock analysis

Ginwa Enterprise Group Inc (600080) currently trades at ¥3.93, while our model-based Fair Value estimate is ¥0.7600, 81% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Economic Profit group reads highest at a median of ¥1.62 per share, and 1 of the 15 models we run sit above the ¥3.93 price.

Bear case: the Dividend Discount group reads lowest at ¥0.4000, and 14 of the 15 models stay below the price. Data coverage for this calculation is low.

Scenario range: ¥0.5300 (bear) to ¥0.9900 (bull), the price of ¥3.93 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Ginwa Enterprise Group Inc reported revenue of 544M CNY in FY2025 versus 534M CNY in FY2021, a compound +0.5%/yr. Reported net income was 15.6M CNY in FY2025.

Key figures

Market cap 1.5B CNY (≈ $220M) Micro · P/E ratio 131.0 · P/S ratio 2.68 · EPS (TTM) ¥0.0300 · Dividend yield 0.8% · Net margin 1.9% · Return on equity 0.6% · Return on assets (EBIT) 0.9% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 24 out of 100 (medium confidence).

What moves the price

The share trades about 57% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −81%, 600080 screens richer than that median.

Fair Value models

The price assumes far more growth than our models allow for, so the models scatter widely (¥0.1900 to ¥7.35). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ¥0.5300 Fair Value ¥0.7600 Bull ¥0.9900
Price ¥3.93 · Downside -80.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income ¥2.28 ¥2.42 ¥2.63 76
EPV ¥0.7900 ¥0.8100 ¥0.8200 74
ROIC Compounder ¥0.7900 ¥0.8100 ¥0.8200 72
All 15 models by family
Earnings-Based
Graham-Dodd ¥0.2800 ¥0.7200 ¥0.9400 65
PEG = 1.0 ¥0.1300 ¥0.1900 ¥0.2500 57
EPV ¥0.7900 ¥0.8100 ¥0.8200 74
Dividend Discount
Gordon GGM ¥0.2600 ¥0.4300 ¥0.6000 68
DDM Multi-Stage ¥0.2600 ¥0.3700 ¥0.4600 67
Multiples
P/E Multiple ¥0.6900 ¥0.9200 ¥1.15 63
P/S Multiple ¥0.5300 ¥0.7100 ¥0.8900 58
P/B Multiple ¥5.52 ¥7.35 ¥9.19 55
EV/EBIT ¥1.00 ¥1.06 ¥1.12 66
EV/EBITDA ¥1.51 ¥1.74 ¥1.97 67
EV/Revenue ¥0.9400 ¥1.00 ¥1.06 54
Asset-Based
NCAV (Graham) ¥0.4500 ¥0.6800 ¥0.8500 55
Economic Profit
Residual Income ¥2.28 ¥2.42 ¥2.63 76
ROIC Compounder ¥0.7900 ¥0.8100 ¥0.8200 72
Growth Earnings
Growth-Adj P/E ¥0.5300 ¥0.7600 ¥0.9900 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 42/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 23
How much profit the company makes from its sales and capital
Quality Growth 25
Are margins and returns getting better?
Cashflow 25
Do the profits arrive as real cash?
Financial strength 72
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 75
How calm the share price moves, does not count
Price momentum 8
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 60
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 8/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−7.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−4.0%
Start year 2020 (pandemic). Over 10 years: −2.9% a year
Revenue growth 31 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.4%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−13.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−14.1%
Dividend (yield on the price)0.8%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−14.1% vs −7.3%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.7% → 1%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Revenue per share shrinking 4.2%/yr over ~10Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.

600080 screens overvalued: fair value 81% below the price. Compare with Merck KGaA →

Compare Ginwa Enterprise Group Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 551 stocks

Beats the industry median on 2/13 measures
Overall it trails its industry peers.
Valuation
Quality Score 42 · Bottom 25%
Fair Value upside −80.7% · Bottom 25%
Profitability
Return on equity (12 months) 0.6% · Below median
Return on assets 0.8% · Below median
Net margin (12 months) 1.9% · Below median
Operating margin (12 months) −5.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −11.4% · Bottom 25%
Dividend yield (12 months) 0.8% · Below median
Balance sheet
Debt / equity 0.03× · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 131.0× · Priciest 25%
P/B 0.94× · Cheapest 25%
P/S (12 months) 2.68× · Pricier than median
EV/EBITDA 62.3× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 15
FUTURE (revenue growth)0 · sector 25
PAST (return on equity)3 · sector 29
HEALTH (low debt)98 · sector 96
DIVIDEND (yield)15 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $113.53 +43% vs 600080
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥49.23 ¥55.21 +12% vs 600080
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,905 ₹1,947 +2% vs 600080
Haleon plc HLN $9.14 $8.61 −6% vs 600080
Merck KGaA MRK €149.20 €109.18 −27% vs 600080
Galderma Group GALD CHF 190.65 CHF 109.86 −42% vs 600080
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs 600080
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs 600080
Sandoz Group SDZ CHF 84.46 CHF 39.70 −53% vs 600080
Divi's Laboratories Limited DIVISLAB ₹11,566 ₹1,567 −86% vs 600080

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Ginwa Enterprise Group Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Ginwa Enterprise Group Inc Fair Value". https://www.fairvalue-calculator.com/stock/600080

Frequently asked questions

Is Ginwa Enterprise Group Inc (600080) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of ¥0.7600 versus a price of ¥3.93, about 81% lower (overvalued).
What is the fair value of 600080?
Our model-based fair value for Ginwa Enterprise Group Inc is ¥0.7600 (as of Nov 6, 2026), built from audited fundamentals. The current price: ¥3.93.
What is the quality score of 600080?
Ginwa Enterprise Group Inc has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ginwa Enterprise Group Inc (600080)?
Our model-based price target is the fair value of ¥0.7600 (as of Nov 6, 2026) from 15 valuation models. Cautious scenario ¥0.5300, optimistic scenario ¥0.9900. It is a calculation from audited fundamentals, not an analyst target.
What is the Ginwa Enterprise Group Inc stock forecast for 2026?
Our models put fair value at ¥0.7600, about 81% lower versus a price of ¥3.93 (overvalued). Cautious scenario ¥0.5300, optimistic scenario ¥0.9900. The calculation is refreshed regularly with new filings.
What is the revenue of Ginwa Enterprise Group Inc (600080)?
Ginwa Enterprise Group Inc reported trailing-twelve-month revenue of about 548M CNY (latest available figure, as of Nov 6, 2026).
Does Ginwa Enterprise Group Inc pay a dividend?
Ginwa Enterprise Group Inc currently shows a dividend yield of 0.76% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Ginwa Enterprise Group Inc (600080)?
Ginwa Enterprise Group Inc pays a dividend of ¥0.03 per share a year, a dividend yield of 0.8%. The payout ratio is 100% of earnings. Our assessment: Token dividend. At a yield of 0.8% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.8% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What is the intrinsic value of Ginwa Enterprise Group Inc (600080)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ginwa Enterprise Group Inc it is ¥0.7600 per share (as of Nov 6, 2026), against a price of ¥3.93. It is the blended result of 15 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Ginwa Enterprise Group Inc stock overvalued or undervalued in 2026?
As of Nov 6, 2026, 600080 trades above its calculated fair value: price ¥3.93, fair value ¥0.7600, a gap of about −81% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 600080?
No. The price is what the market pays today (¥3.93); the fair value is what the company's own numbers justify (¥0.7600). For Ginwa Enterprise Group Inc the two are ¥3.17 per share apart. That gap is exactly why we show both numbers side by side.
How much is Ginwa Enterprise Group Inc worth?
The market values Ginwa Enterprise Group Inc at about 1.5B CNY (market capitalisation, as of Nov 6, 2026). Per share that is ¥3.93; our models calculate a fair value of ¥0.7600 per share.
What do the bullish and bearish scenarios say about 600080?
Our models span a range for Ginwa Enterprise Group Inc: cautious scenario ¥0.5300, base ¥0.7600, optimistic ¥0.9900 per share (as of Nov 6, 2026, price ¥3.93). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 600080?
Ginwa Enterprise Group Inc trades at a price-to-earnings ratio of 131.0 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥0.7600 is built from several models across several years. Median P/E at fiscal year-end, 8 fiscal years (2016 to 2025), reported earnings: 74.7. Other multiples: P/B 0.9, P/S 2.7, EV/EBITDA 62.3.
How solid is the balance sheet of Ginwa Enterprise Group Inc (600080)?
Balance-sheet figures for Ginwa Enterprise Group Inc (as of Nov 6, 2026): return on equity 0.6%, debt of 0.03 per unit of equity. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is 600080 from its 52-week high?
Ginwa Enterprise Group Inc trades at ¥3.93, about 57% below its 52-week high of ¥9.16 and 1% above the low of ¥3.90 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of ¥0.7600 is for.
Which stocks are comparable to Ginwa Enterprise Group Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ginwa Enterprise Group Inc stock attractive at the current price?
The data as of Nov 6, 2026: price ¥3.93, calculated fair value ¥0.7600 (−81%), Quality Score 42/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 600080 calculated?
We run Ginwa Enterprise Group Inc through 15 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥0.7600 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Ginwa Enterprise Group Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ginwa Enterprise Group Inc (600080)?
The closing price on Nov 9, 2026 was ¥3.93. Our model-based fair value is ¥0.7600, about 81% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ginwa Enterprise Group Inc right now?
The price sits above even our optimistic bull case (¥0.9900). The favourable scenario is already priced in. Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (¥0.5300 to ¥0.9900) leaves room in how you read the outcome.

Key figures of Ginwa Enterprise Group Inc

How large is the market capitalisation of Ginwa Enterprise Group Inc (600080)?
The market capitalisation of Ginwa Enterprise Group Inc is 1.5B CNY (≈ $220M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ginwa Enterprise Group Inc (600080)?
The price-to-sales ratio of Ginwa Enterprise Group Inc is 2.68 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Ginwa Enterprise Group Inc (600080)?
Earnings per share at Ginwa Enterprise Group Inc are ¥0.0300 (price ÷ EPS = P/E 131.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Ginwa Enterprise Group Inc (600080)?
The dividend yield of Ginwa Enterprise Group Inc is 0.8% (payout 100%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Ginwa Enterprise Group Inc (600080)?
The net margin of Ginwa Enterprise Group Inc is 1.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ginwa Enterprise Group Inc (600080)?
The return on equity (ROE) of Ginwa Enterprise Group Inc is 0.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ginwa Enterprise Group Inc (600080)?
On an EBIT basis the return on assets of Ginwa Enterprise Group Inc is 0.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ginwa Enterprise Group Inc (600080)?
The operating margin of Ginwa Enterprise Group Inc is −5.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ginwa Enterprise Group Inc (600080)?
Revenue at Ginwa Enterprise Group Inc is growing −11.4% versus a year earlier (3y avg −2.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Ginwa Enterprise Group Inc (600080)?
Earnings per share at Ginwa Enterprise Group Inc are growing +224% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Ginwa Enterprise Group Inc (600080) generate?
The free cash flow of Ginwa Enterprise Group Inc is −100M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Ginwa Enterprise Group Inc (600080) hold?
Ginwa Enterprise Group Inc holds more cash than debt, 304M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Ginwa Enterprise Group Inc in the live analysis

One click puts Ginwa Enterprise Group Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.